**Name of Journal: *World Journal of Diabetes***

**ESPS Manuscript No: 26117**

**Manuscript Type: REVIEW**

**Evidence for current diagnostic criteria of diabetes mellitus**

Kumar R *et al.* Diagnostic criteria for diabetes

**Ritesh Kumar, Lakshmana Perumal Nandhini, Sadishkumar Kamalanathan, Jayaprakash Sahoo, Muthupillai Vivekanadan**

**Ritesh Kumar, Lakshmana Perumal Nandhini, Sadishkumar Kamalanathan, Jayaprakash Sahoo, Muthupillai Vivekanadan,** Department of Endocrinology and Metabolism, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry 605006, India

**Author contributions:** Kumar R, Nandhini LP, Kamalanathan S, Sahoo J and Vivekanadan M contributed to conception and design, drafting the article and final approval of the manuscript.

**Conflict-of-interest** **statement:** None.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to: Jayaprakash Sahoo, Assistant Professor,** Department of Endocrinology and Metabolism, Jawaharlal Institute of Postgraduate Medical Education and Research, Dhanvantari Nagar, Pondicherry 605006, India. [jppgi@yahoo.com](mailto:jppgi@yahoo.com)

**Telephone:** +91-0413-2297374

**Fax:** +91-0413-2272067

**Received:** March 28, 2016

**Peer-review started:** March 30, 2016

**First decision:** May 17, 2016

**Revised:** June 29, 2016

**Accepted:** July 14, 2016

**Article in press:**

**Published online:**

**Abstract**

Diabetes mellitus is a non-communicable metabolic derangement afflicting several millions of individuals globally. It is associated with several micro and macrovascular complications and is also a leading cause of mortality. The unresolved issue is that of definition of the diagnostic threshold for diabetes. The World Health Organization and the American Diabetes Association (ADA) have laid down several diagnostic criteria for diagnosing diabetes and prediabetes based on the accumulating body of evidence.This review has attempted to analyse the scientific evidence supporting the justification of these differing criteria. The evidence for diagnosing diabetes is strong, and there is a concordance between the two professional bodies. The controversy arises when describing the normal lower limit of fasting plasma glucose (FPG) with little evidence favouring the reduction of the FPG by the ADA. Several studies have also shown the development of complications specific for diabetes in patients with prediabetes as defined by the current criteria though there is a significant overlap of such prevalence in individuals with normoglycemia. Large multinational longitudinal prospective studies involving subjects without diabetes and retinopathy at baseline will ideally help identify the threshold of glycemic measurements for future development of diabetes and its complications.

**Key words:** Diabetes; Prediabetes; Post glucose; Microvascular complications; Macrovascular complications

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The diagnostic criteria for diabetes and prediabetes have evolved along the timeline taking into account new evidences which had developed. The major professional bodies have converged on to a consensus in developing the different thresholds for diagnosis of diabetes and associated states. Nevertheless,controversy remains on certain issues. There is need to review the evolution of these criteria, the logistics behind their adoption and their association with different complications.

Kumar R, Nandhini LP, Kamalanathan S, Sahoo J, Vivekanadan M. Evidence for current diagnostic criteria of diabetes mellitus. *World J Diabetes* 2016; In press

**INTRODUCTION**

Diabetes mellitus (DM) is a classic non-communicable disease that contributes to morbidity, mortality and poor quality of life apart from imposing economic burden on the health care system. The prevalence of type 2 DM is rising steadfast at an alarming rate and is estimated to affect 592 million individuals globally by the year 2035[1]. The International Diabetes Federation (IDF) projections of the prevalence of prediabetes are expected to reach 471 million by 2035[1]. It is essential to make an early diagnosis and begin intervention to avoid complications of DM. But, defining the diagnostic threshold for diabetes and prediabetes has been a matter of intense debate. In this regard, several professional bodies have published differing diagnostic criteria over the last few decades. Below, is a review of the evolution of various diagnostic criteria and their validity.

**EVOLUTION OF DIAGNOSTIC CRITERIA FOR DIABETES**

In ancient times, DM was diagnosed by tasting urine.Then the diagnosis was made by estimation of glucose in urine.But urine glycosuria did not correlate with glucose level in blood and was replaced by estimation of plasma glucose.

***WHO criteria (1965)***

The World Health Organization (WHO) in 1965 proposed the first widely accepted laboratory standard for diagnosing DM (Table 1). The committee recommended diagnosing DM in persons under the age of 45 years if 2 h venous plasma glucose was ≥ 7.22 mmol/L after loading with oral glucose of 50 or 100 g[2]. In persons aged more than 45 years, the committee considered that other clinical data should be the main guide to the diagnosis. Borderline state was defined if 2 h plasma glucose level was between 6.11 to 7.17 mmol/L.

***NDDG criteria (1979)***

The National Diabetes Data Group (NDDG) in 1979 proposed new diagnostic criteria for DM[3]. It was based on the bimodal distribution of plasma glucose observed in Pima Indians and Nauruan population and the risk of progression of DM and its complications[4,5]. A subject was diagnosed as having DM if fasting plasma glucose (FPG) was ≥ 7.78 mmol/L and/or 2-h plasma glucose (2-h PG) after 75 g of glucose was ≥ 11.11 mmol/L.

A study on Pima Indians revealed that the 2-h PG level differentiated those with DM from those without[4]. Subjects fall into two groups, one with a distribution of 2-h PG levels below 11.11 mmol/L, and the other with a distribution above 13.33 mmol/L. Diabetic retinopathy was mainly confined to the second group, i.e. in subjects whose 2-h PG level ≥ 13.33 mmol/L and this value divided the subjects with diabetes from nondiabetics. This bimodal distribution was further confirmed in Nauruan population[5]. Similar bimodal distribution also exists for FPG, where the glycemic thresold of about 7.78 mmol/L divides the two groups.Later, the bimodal glycemic distribution was reconfirmed from other populations with a high prevalence of DM like Mexican Americans[6], Pacific Islanders[7], South African Indians[8], Egyptians[9], Malaysians[10] and Americans in the United States[11]. However, for some populations, no such bimodality could be documented[12].

With accumulating evidence from further studies, it was recognized that several individuals had 2-h PG levels that were intermediate between the normal and diabetic range.This group of individuals had 1%-5% risk of progression to DM per year though the majority continued to remain in this state and a few reverted to normalcy. It was also noted that there was an increased prevalence of atherosclerotic disease and electrocardiographic abnormalities and death in this population. This provided a window of opportunity to identify such individuals to intervene early and prevent progression to DM and its complications. To lay emphasis on this, the terminology “impaired glucose tolerance” (IGT) was first introduced by the NDDG of the National Institute of Health, United States. It was defined as a state of having venous FPG level of less than 7.8 mmol/L and a 2-h PG OGTT value between 7.8 mmol/L and 11.1 mmol/L[3].

This group also aimed to standardize the protocol for OGTT internationally and recommended using 75 g of anhydrous glucose load for testing in nonpregnant adults. This was based on the observation that 50-g dose was not adequate in many individuals to identify IGT detected using the larger dose. Also, 100-g dose resulted in significant nausea in several study subjects. In subjects without diabetes it was reported that 50 g or 100 g result in aproximaltely similar plasma glucose levels, the only difference was that 2 h PG was 0.83 mmol/L higher for 100 g as compared to 50 g oral glucose load[13,14]. Also there were no significant differences between 75- and 100-g doses. But in subjects with IGT there was higher difference (up to 2.78 mmol/L) in 2-h PG value between the 50 and 100 g oral glucose[3].

***WHO criteria (1980 and 1985)***

The WHO technical recommendation released in 1980 modified the criteria for diagnosing DM (Table 1). A venous FPG value above 8 mmol/L and a post glucose load 2-h PG value above 11 mmol/L were considered diagnostic of DM. This 2-h PG value was chosen based on observations that specific complications of DM rarely developed below this threshold. The term “IGT” suggested by the NDDG was also endorsed by WHO and became a part of the recommendation[15]. This was further slightly modified in the subsequent recommendations in 1985 and fasting and 2-h post glucose load venous plasma glucose thresholds were redefined as 7.8 mmol/L and 11.1 mmol/L respectively (Table 1)[16].

***ADA criteria (1997) and WHO criteria (1999)***

In 1997, the American Diabetes Association (ADA) lowered the threshold for FPG from 7.8 to 7.0 mmol/L and the 2-h post glucose load value was retained (Table 1)[17]. Impaired fasting glucose (IFG) was defined as FPG ≥ 6.1 mmol/L and < 7.0 mmol/L (Table 1). WHO adopted these criteria for the diagnosis of diabetes and prediabetes in 1999. In the second National Health and Nutrition Examination Survey (NHANES-II), only 26% of people with newly diagnosed DM by 1985 WHO had FPG ≥ 7.8 mmol/L, whereas 97% had 2-h PG ≥ 11.1 mmol/L[18]. Other studies also reported that as many as 80% of DM cases discovered in population screening by OGTT have FPG < 7.8 mmol/L[19–25]. Thus, the cutpoint of FPG > 7.8 mmol/L defined a greater degree of hyperglycemia than did the cutpoint of 2-h PG > 11.1 mmol/L. Thus, FPG appeared to be an insensitive test in population screening for undiagnosed DM.

This revision of the diagnostic criteria for the FPG from 7.8 to 7.0 mmol/L was based on the assumption that the threshold of the FPG and 2-h PG should identify similar conditions. In Pima Indians[26], Egyptians[9] and NHANES-III, both FPG and 2-h PG were strongly associated with retinopathy. The cutpoint for the 2-h PG was justified largely because of the dramatic increase in the prevalence of retinopathy approximately around that point. The equivalent cutpoint of FPG for 2-h PG level predicting retinopathy was computed in population studies of the Pima Indians, Egyptians, Pacific population, and NHANES III participants.

***ADA criteria (2003)***

A controversial change was brought out in the 2003 ADA guidelines, and it was the reduction in the cut-off point for defining the upper limit of FPG (Table 1). Based on four population-based epidemiological studies, the ideal cut-off point was shown to fall between 5.22-5.72 mmol/L and based on this data, an arbitrary cut-off of 5.55 mmol/L was chosen as the new threshold[27]. The lower threshold value of IFG was reduced from 6.11 to 5.55 mmol/L.

The phases of IFG and IGT represent metabolic states intermediate between normal glucose homeostasis and diabetic hyperglycaemia. The physiological basis of IFG and IGT are different. IFG is associated with insulin resistance at liver while IGT is associated with peripheral insulin resistance, at the level of skeletal muscle. The rationale for establishing the intermediate categories of impaired glucose regulation was based on their ability to predict future diabetes and its complications. The idea behind selecting the lower limit of IFG would be the identification of a threshold of FPG at which the risk of development of DM and complication or metabolic rises sharply. Data from Mauritius[28] and DECODE study[29] indicate that such a threshold of FPG does not exist for cardiovascular risk factors, all-cause mortality, or future DM. This criterion was based on receiver operating characteristics (ROC) curve analyses of Pima Indian, Mauritius, San Antonio and Hoorn study data, which identified the baseline FPG levels, which maximised sensitivity and specificity for predicting DM over a 5-year period[25]. The ROC curve analyses indicated that a cut-point of 5.4-5.5 mmol/L gives the best combination of sensitivity and specificity for predicting future DM.

***ADA criteria (2010) and WHO criteria (2011)***

International Expert Committee (IEC 2009)[30], ADA in 2010 and WHO in 2011 recommended a glycated hemoglobin (HbA1c) level of ≥ 6.5% as a diagnostic cut-off for DM (Table 1). HbA1c level reflects the average plasma glucose level over preceding three months. HbA1C is more convient than glucose because it does not require fasting samples and is also not affected by recent changes in diet or activity. Another limitation of plasma glucose assay is lack of consistent accuracy of assay[31]. HbA1C has a greater analytic stability and less day-to-day variability in comparison to plasma glucose[32]. Selvin *et al*[33] evaluated the variabilities of glycemic measurement and found that 2-h PG levels [within-person coefficient of variation (CV), 16.7%; 95% confidence interval (CI): 15.0 to 18.3] and FPG (CV, 5.7%; 95%CI: 5.3 to 6.1) had substantially more variability compared with HbA1c (CV, 3.6%; 95%CI: 3.2 to 4.0) levels.

**HBA1C *VS* GLUCOSE CUTPOINTS FOR DIAGNOSIS OF DM**

Lorenzo *et al*[34] compared 1999 WHO (2-h PG ≥ 11.11 mmol/L) and 2003 ADA criteria (FPG ≥ 7 mmol/L) with an HbA1C of ≥ 6.5%. It was found that sensivity of HbA1C is poorer than plasma glucose because HbA1c diagnosed 5.2% of subjects as having diabetes compared to FPG (7.1%) and the 2-h PG (15.4%). Kramer *et al*[35] reported the sensitivity and specificity of HbA1c cutoff of 6.5% were 44% and 79% respectively based on the Rancho Bernardo Study. According to the ADA criteria, for this given HbA1C cut point of 6.5%, 85% of participants were classified as nondiabetic. Olson *et al*[36] compared HbA1C and standard OGTT for diagnosis of DM in three datasets from the prospective Screening for IGT study (*n* = 1581), NHANES-III (*n* = 2014), and NHANES 2005-2006 (*n* = 1111) and reported that HbA1C criterion failed to recognize upto 70% of cases of DM. In conclusion, from above studies, HbA1C had the least sensitivity for diagnosis of DM in comparison to FPG and 2-h PG. Several studies have shown that HbA1C levels, as the plasma glucose levels, can predict the development of future DM[37,38].

A limitation of HbA1c is that it is affected by red blood cell disorders[39]. Another limitation of HbA1c is that its levels depend on genetic factors[40,41].It also suffers from analytic imprecision if methods other than high-performance liquid chromatography is used for estimation and if such tests are not standardized. Measurement of HbA1C is currently well standardized with the adaptation of “national glycohemoglobin standardization program” protocols.

**OPTIMAL THRESHOLD OF THE HBA1C FOR RETINOPATHY**

The most important question is how well HbA1c predicts retinopathy.IEC suggested a cutoff of the HbA1C of 6.5% for the diagnosis of DM because it was presumed that diabetic retinopathy sharply increased above this level. Unfortunately, most of the studies are cross-sectional studies and only a few prospective studies looked at the relationship between HbA1c and retinopathy (Table 2). Longitudinal prospective studies with subjects without DM and retinopathy at baseline will ideally give the association of HbA1C and retinopathy.

**CROSS-SECTIONAL STUDIES OF HBA1C FOR RETINOPATHY PREDICTION**

Colagiuri *et al*[42] analysed the pooled data of nine studies and find that diabetes-specific retinopathy (after exclusion of mild retinopathy) was observed over the HbA1C range of 6.3% to 6.7% based on vignitile distribution and 6.4% by ROC analysis. He concluded that HbA1c ≥ 6.5% is a suitable alternative diagnostic criterion for DM. In the Australian Diabetes Obesity and Lifestyle study (AusDiab), retinopathy was assessed in 2182 participants aged ≥ 25 years. DM was not excluded in this study. The thresholds for increasing the prevalence of retinopathy was 6.1% for HbA1C[43]. Sabanayagam *et al*[44] examined the relationship of HbA1C to retinopathy in population-based sample of 3190 Malay adults aged 40-80 years in Singapore. HbA1C cut-off point of 6.6% detected mild retinopathy [87.0% sensitivity, 77.1% specificity and area under curve (AUC) 0.899] and 7.0% detected moderate retinopathy (82.9% sensitivity, 82.3% specificity and AUC 0.904). The prevalence of mild and moderate retinopathy was < 1% below the optimal cut-off points. Xin *et al*[45] in Chinese population and Cho *et al*[46] in South Korean population found a threshold of 6.5 % for detection of retinopathy. In ARIC study[47], lower AUC was found (0.561 for any retinopathy, 0.543 for mild retinopathy and 0.658 for moderate) to severe retinopathy. These studies show that though there is an association between HbA1C and retinopathy, an optimal threshold could not be established.

**LONGITUDINAL STUDIES OF HBA1C FOR RETINOPATHY PREDICTION**

Tsugawa *et al*[48] analyzed longitudinal data of 19897 Japanese adults who underwent a health checkup in 2006 and were followed up three years later. Logistic regression analysis found that individuals with HbA1c levels of 6.5%-6.9% were at significantly higher risk of developing retinopathy at 3 years compared with those with HbA1c levels of 5.0%-5.4% [adjusted odds ratio, 2.35 (95%CI: 1.08-5.11)]. The incidence of retinopathy was determined in 233 individuals, aged 50 to 74 years, by ophthalmoscopy and fundus photography at baseline and after an average follow-up of 9.4 years in the Hoorn study[49]. Incidence of retinopathy was found to be significantly increased for HbA1c ranging between 5.8%-13.1% compared to HbA1C between 4.3%-5.2% but no optimal thresold of HbA1c was determined as the number of subjects in the study was not adequate.

Thresholds of HbA1c for retinopathy differ widely in the studies because of several reasons. First, different statistical methods were used in different studies. For example, in AusDiab study[43], the cutoff was 6.1% by visual inspection, but cutoff was changed when change-point models were used. Without any adjustment, a threshold of 5.2% was calculated by using a change point model. After adjustment for age, sex and systolic blood pressure, the threshold for HbA1c was observed at 5.6% (95%CI: 3.9-6.2, *P* = 0.092) and after further adjustment for diabetes duration, the threshold rose to 6.0% (3.9-7.0, *P* = 0.064). Study on Pima Indians, Egyptians and in DETECT-2 study,cutoff of HbA1C were determined without any adjustment. Second, the threshold of HbA1C depends widely on the definition of retinopathy. Mild retinopathy is not specific for DM as it has been documented in non diabetic individuals too. Thresholds of HbA1c for mild, moderate and severe retinopathy can differ.For example, in Malay population thresholds of HbA1c were 6.6% and 7.0% respectively for mild and moderate retinopathy[44]. Also, the criteria for grading of retinopathy is different in different studies.

Third, the distributions of HbA1C may not be the same for different ethnicities. For example, Tsugawa *et al*[41] in cross-sectional study examined the relationships between HbA1c level and the prevalence of retinopathy in black and white United States adults. 2804 white persons and 1008 black persons above 40 years of age were included in the study. After adjustment for age, sex, hypertension,body mass index (BMI), family history of DM, and use of antidiabetes medications or insulin, the lowest HbA1c category for which the prevalence of retinopathy was significantly higher than the reference category (< 5.5%) was 6.0% to 6.4% for white persons (risk difference, 4.8% 95%CI: 0.5% to 9.1%) and 5.5% to 5.9% for black persons (risk difference, 5.3%CI: 1.0% to 9.5%). It was noted that the prevalence of retinopathy was higher at a lower HbA1c level in black Americans when compared white Americans. However, Bower *et al*[50] did not find any ethnic differences in the relationship of HbA1C with retinopathy in non-Hispanic white,non-Hispanic black and Hispanic American participants aged ≥ 40 years from the 2005-2008 NHANES. Finally, differences in threshold of HbA1C might be due to lack of standardization of HbA1c measurements, especially in older studies.

**HBA1C AND MACROVASCULAR COMPLICATIONS**

Chronic hyperglycemia is a risk factor for adverse cardiovascular outcomes and mortality. A meta-analysis of 26 prospective studies assessed the association between HbA1c and major cardiovascular outcomes including all-cause mortality, incident CVD, CVD mortality, incident stroke and peripheral arterial disease. Only studies that followed up patients for more than 5 years were included. It was found that for every 1% increase in HbA1c, there was a 15% increase in hazard of all-cause mortality, 25% increase in CVD mortality, 17% in CVD, 17% in fatal CHD and 29% increase in PVD[51]. A positive dose response relationship was also noticed between HbA1c and the outcome measures and is an independent risk factor for adverse cardiovascular outcomes. Similar findings were noted in another meta-analysis by Selvin *et al*[52].

**PREDIABETES AND RISK OF COMPLICATIONS**

The association of complications is not restricted to glucose levels above the diabetic threshold.It is a continuum, which continues in IGT and IFG range.Indeed, complications have also been documented in normal population,although of diminished magnitude. Various studies have looked into the paradigm of prediabetes forecasting the risks of micro and macrovascular complications of diabetes.

**PREDIABETES AND RISK OF DIABETIC RETINOPATHY**

The occurrence of microvascular complications associated with established DM is well known. However, such complications of dysglycemia have also been noted in patients who currently fall within the spectrum of prediabetes. The Diabetes Prevention Programme followed up individuals known to have prediabetes and analysed a subset of them for development of diabetic retinopathy. Seven point nine percent of patients had evidence of retinopathy as defined as ETDRS level 20[53]. One percent of the study population noted to have mild/moderate diabetic retinopathy as defined by ETDRS level 35-43. The Blue mountains eye study, a population-based survey of common eye diseases conducted in Australia, screened 3275 participants without DM for retinopathy lesions using six field fundus photographs. Microaneurysms were seen in 6.8% of nondiabetic population[54]. These studies defined retinopathy based on the presence of absence of microaneurysms, and it is to be noted that they are not specific for diabetic retinopathy and may occur in patients with systemic hypertension.In some studies, they have been shown to be related to atherosclerosis and carotid disease.

A population-based cross sectional survey of prevalence of DM, risk factors and associated conditions was done in the AusDiab study[55]. All participants detected to have DM and prediabetes and few with normal glucose tolerance (as defined by WHO 1999 criteria) were screened for retinopathy. Fundus photographs included two fields per eye, namely the macula and nasal to disc were graded according to Wisconsin criteria. The prevalence of diabetic retinopathy was 6.7% (95%CI: 5.3%-8.4%) in patients with prediabetes[56]. The prevalence of retinopathy was 5.8% in the population with normal glucose tolerance (95%CI: 3.7%-8.5%)[57].

The Gutenberg health study (GHS), is a prospective population-based observational study conducted in a single centre in Germany that initially included 15010 individuals with the aim of studying ocular, cardiovascular, psychosomatic and immune disorders. A sub-cohort of 5000 individuals were analyzed to study the prevalence of retinopathy in those diagnosed to have prediabetes as defined by HbA1c value ranging from 5.7%-6.4% and its association with cardiovascular risk factors. Twenty-two point four percent of participants were diagnosed to have prediabetes based on the HbA1c criteria. 82.9% of those with prediabetes were assessed for evidence of retinopathy by 3-field fundus photograph, and 8.2% were found to have diabetic retinopathy. None of the participants had evidence of proliferative diabetic retinopathy. Though there was no statistically significant difference in the prevalence of cardiovascular risk factors between those with and without retinopathy, the number of participants with retinopathy was too small to draw any conclusion[58].

**DIABETIC REINOPATHY CHANGES IN NORMOGLYCEMIA**

However, the retinal vascular changes seen in diabetic patients, termed isolated retinopathy signs, are often seen in individuals without DM or hypertension. The prevalence of these signs has been documented to range between 2.6%-8.6% in individuals without DM or hypertension. Such isolated retinopathy signs are often transient and on follow-up of these individuals, 40%-70% of such signs may resolve spontaneously[59,60].

The Beaver Dam Eye study was a cross-sectional population-based study that investigated the association between retinopathy lesions and hypertension among non-diabetic individuals. Among the 4926 persons examined, 7.8% had evidence of retinopathy, and there was a significant association with systemic hypertension[61].Similar prevalence was also seen in the Blue Mountains eye study where 3654 individuals from Sydney, Australia were screened for retinopathy using six field fundus photography. Retinal hemorrhages and microaneurysms were noted in 9.9% of individuals, and a significant positive relationship was noted between retinopathy and hypertension. However, DM was defined based on the FPG level > 7.8 mmol/L alone which could have resulted in mislabeling a significant proportion of individuals with DM as non-diabetics according to the current definitions[54].

A follow-up of this cohort, where 2335 persons were re-examined reported a cumulative 5 year incidence of retinopathy as 9.7% and no significant association was found between incident retinopathy and blood glucose level or hypertension. The lack of a demonstrable association with hypertension could have resulted from inadequate power of the study. Among those with retinopathy at baseline, 3.5% had developed DM during the intervening five year period, and the retinopathy lesions had regressed or remained unchanged in 72.3%[59]. The ARIC study had reported the three-year incidence of retinopathy in non-diabetic subjects as 2.9% and also showed an association between retinopathy and hypertension and fasting blood glucose levels. Forty-three percent of any retinopathy signs seen among patients at baseline had regressed at the end of three years. This was found to be related to lower levels of cardiovascular risk factors[60].

Whether these changes of retinopathy signify an increased risk of progression to DM is debatable. Most studies have shown no such association.However, retinopathy was predictive of incident DM in persons with a positive family history of DM during the follow-up of the ARIC cohort. The incidence of DM was 10.4% among those with a family history of DM compared to 4.8% among those without a positive family history after a follow up of 3 years[62]. Similarly, the Beaver Dam study assessed the 15-year cumulative incidence of DM and hypertension among those with evidence of any retinopathy at baseline and found a significant association between incident DM and retinopathy among those < 65 years of age (24.3% *vs* 11.1%)[63].

**PREDIABETES AND RISK OF NEPHROPATHY**

The prevalence of nephropathy is increased in individuals diagnosed to have prediabetes compared to normal individuals. The NHANES data analysis revealed the prevalence of chronic kidney disease (as defined by glomerular filtration rate using “modification in renal diet in renal diseases” equation) in newly detected prediabetes to be 17.1% compared to 11.8% in those without DM and 24.2% in newly detected DM, after adjustment for age, gender and race. However, the diagnosis of prediabetes was based on measurement of FPG alone which could have underestimated the prevalence of prediabetes in the study. The other important risk factor for chronic kidney disease, namely hypertension was documented based on self-reporting by study participants which could have again biased the results of the study. Nevertheless, the prevalence of CKD increases across the spectrum of dysglycemia[64].

Few studies have shown that early kidney injury characterized by hyperfiltration is seen in those with prediabetes. Among the 1560 individuals included in the Renal Iohexol Clearance Survey in Tromso 6 (RENIS-T6) study, it was seen that individuals with IFG had evidence of hyperfiltration (defined as GFR > 90th percentile determined by Iohexol method and adjusted for age, weight, height and use of renin-angiotensin inhibitors) when compared to those with normal glucose[65]. Similar results were obtained in the Huaian Diabetes Prevention program from China, where 5431 subjects were included to analyze the association between HbA1c level and renal hyperfiltration. The study had reported a positive correlation between HbA1c level and hyperfiltration independent of other parameters like age, sex, hypertension, BMI and lipid profile. The odds of hyperfiltration was 2.34 times higher in persons with HbA1c level of 6.21%-6.49% compared to those with A1c < 5.7%[66]. This indicates that chronic hyperglycemia is associated with hyperfiltration in addition to the acute effect of hyperglycemia that has been even in healthy subjects[67].

Microalbuminuria, another marker of kidney injury, has also been found to be associated with prediabetic state. A study from New Zealand determined the prevalence of microalbuminuria and its association with other risk factors like ethnicity, glycemic status, hypertension, obesity and life style factors. Individuals with IGT had a higher prevalence of microalbuminuria when compared to those with normal glycemic status (16.1% *vs* 4.0%) and glycemic status was found to be the most important determining factor of microalbuminuria in multivariate regression analysis[68]. However, contrary to the results of the above-mentioned studies, a study from Korea did not find any significant association between microalbuminuria and prediabetes. Forty-five percent of participants were diagnosed to have prediabetes based on ADA criteria for FPG and HbA1c inthe Fifth Korea National Health and Nutrition Examination Survey (KNHANES V). Though the prevalence of microalbuminuria was higher in the prediabetic group when compared to the normal group (6.3% *vs* 3.6%), this difference was not seen following the adjustment for hypertension[69].

**PREDIABETES AND RISK OF NEUROPATHY**

Nerve conduction study conducted in 58 subjects from India with prediabetes as defined by the WHO criteria detected evidence of neuropathy in 32.8% of subjects which was evaluated by quantitative sensory testing (QST) and autonomic function tests. Autonomic neuropathy was evident in 8% of individuals, and QST was abnormal in 27.6% of subjects[70].

**PREDIABETES AND RISK OF CARDIOVASCULAR DISEASES**

Both IGT and IFG are associated with an increased risk of developing adverse cardiac events. A few studies have shown that patients with IGT have a greater risk when compared to patients with IFG. The risk also seems comparable to those with DM. Individuals with prediabetes were shown to have evidence of subclinical arteriosclerosis as measured by cardio-ankle vascular index (CAVI) in a recent study from Japan. CAVI is a sensitive indicator of arterial wall stiffness that is independent of blood pressure changes[71]. The odds of having high CAVI score among those with prediabetes is 1.29 (95%CI: 1.11-1.48) in men and 1.14 (95%CI: 1.01-1.28) for women compared to 2.41 (CI: 1.97-2.95) in men and 2.52 (CI: 1.94-3.28) for women with DM[72].

Subclinical myocardial infarctions, defined as those unrecognized by the patient and the physicians are harbingers of major cardiovascular events in the future. The Multi-ethnic study of atherosclerosis (MESA) was instituted to study the prevalence and progression of subclinical cardiovascular disease in a population-based cohort from the United States of America[73]. In this cohort, the prevalence of unrecognized myocardial infarction detected based on electrocardiographic changes was found to be higher among those with IFG when compared to those with normal fasting glucose level (3.5% *vs* 1.4%) and this relationship persisted even after adjusting for other confounding risk factors[74].

Increased risk of cardiovascular disease and all-cause mortality with abnormal glucose metabolism was documented in the AusDiab study after a median follow-up of 5.2 years. IFG was found to be an independent predictor of cardiovascular disease (CVD) mortality with a hazard ratio of 2.5 (95%CI: 1.2-5.1) after adjusting for other risk factors for CVD. However, IGT was not found to be associated with increased CVD mortality[75].

A meta-analysis of studies evaluating the risk of coronary artery disease (CAD) associated with IFG as defined by the ADA and the WHO included 17 prospective studies. The risk of CAD was found to be increased in participants with IFG as defined by both criteria. The relative risk of CAD with IFG was 1.11 (95%CI: 1.02-1.21) using the ADA criteria and was 1.18 (95%CI: 1.10-1.28) when applying the WHO criteria. However, sub group analysis showed that the increased risk of CAD with IFG was not seen in studies that had excluded individuals with elevated 2-h plasma glucose. And further, the risk of CAD with IFG was not found to be significant when adjusted for other CAD risk factors[76]. A similar meta-analysis of studies analyzing the risk of stroke with prediabetes, an increased risk was seen in those studies which had defined prediabetes according to the WHO criteria (FPG 6.11-6.94 mmol/L). The risk was found to be increased in those with IGT and those with both IGT and IFG[77].

**CONCLUSION**

Current diagnostic criteria for DM or intermediate hyperglycemia is based on threshold of FPG, 2-h PG and HbA1C for diabetic complications,especially retinopathy. Controversies in diagnostic criteria are due to differences in inclusion criteria, different ethnic populations being studied, background prevalence of DM, definition of retinopathy used and statistical methods utilized. Therefore, there is a need to adopt uniform methodologies in studies across the globe to get universally comparable and interpretable results. Possibly, large longitudinal prospective studies involving subjects from different ethnicities, without diabetes and retinopathy at baseline will ideally help identify the threshold of glycemic measurements (FPG, 2 h-PG and HbA1C) for future development of diabetes and its complications. Definition of retinopathy especially related to diabetes must be standardized universally. Further research is needed to understand better the pathophysiology of IFG and IGT. It is not well understood whether IFG and IGT are distinct metabolic abnormalities or they are parts of continuum. The factors predicting the development of future diabetes and its complications from IGT and IFG is also not well understood. This risk might be better assessed by the use of prediction scores which are weighted according to the glycemic measurements, other risk factors, and clinical features including complications. Finally, the extent to which,future DM and its complications, especially cardiovascular diseases can be prevented by adoption of modification of thresholds are not yet known.

New data from properly designed studies may help in revision of diagnostic criteria in future.

**REFERENCES**

1 **Guariguata L**, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. *Diabetes Res Clin Pract* 2014; **103**: 137-149 [PMID: 24630390 DOI: 10.1016/j.diabres.2013.11.002]

2 Diabetes mellitus. Report of a WHO expert committee. *World Health Organ Tech Rep Ser* 1965; **310**: 1-44 [PMID: 4953441]

3 Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. *Diabetes* 1979; **28**: 1039-1057 [PMID: 510803 DOI: 10.2337/diab.28.12.1039]

4 **Bennett PH**, Rushforth NB, Miller M, LeCompte PM. Epidemiologic studies of diabetes in the Pima Indians. *Recent Prog Horm Res* 1976; **32**: 333-376 [PMID: 986678 DOI: 10.1016/b978-0-12-571132-6.50021-x]

5 **Zimmet P**, Whitehouse S. Bimodality of fasting and two-hour glucose tolerance distributions in a Micronesian population. *Diabetes* 1978; **27**: 793-800 [PMID: 680406 DOI: 10.2337/diab.27.8.793]

6 **Rosenthal M**, McMahan CA, Stern MP, Eifler CW, Haffner SM, Hazuda HP, Franco LJ. Evidence of bimodality of two hour plasma glucose concentrations in Mexican Americans: results from the San Antonio Heart study. *J Chronic Dis* 1985; **38**: 5-16 [PMID: 3972950 DOI: 10.1016/0021-9681(85)90003-7]

7 **Raper LR**, Taylor R, Zimmet P, Milne B, Balkau B. Bimodality in glucose tolerance distributions in the urban Polynesian population of Western Samoa. *Diabetes Res* 1984; **1**: 19-26 [PMID: 6529881]

8 **Omar MA**, Seedat MA, Dyer RB, Motala AA, Knight LT, Becker PJ. South African Indians show a high prevalence of NIDDM and bimodality in plasma glucose distribution patterns. *Diabetes Care* 1994; **17**: 70-73 [PMID: 8112193 DOI: 10.2337/diacare.17.1.70]

9 **Engelgau MM**, Thompson TJ, Herman WH, Boyle JP, Aubert RE, Kenny SJ, Badran A, Sous ES, Ali MA. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited. *Diabetes Care* 1997; **20**: 785-791 [PMID: 9135943 DOI: 10.2337/diacare.20.5.785]

10 **Lim TO**, Bakri R, Morad Z, Hamid MA. Bimodality in blood glucose distribution: is it universal? *Diabetes Care* 2002; **25**: 2212-2217 [PMID: 12453963 DOI: 10.2337/diacare.25.12.2212]

11 **Fan J**, May SJ, Zhou Y, Barrett-Connor E. Bimodality of 2-h plasma glucose distributions in whites: the Rancho Bernardo study. *Diabetes Care* 2005; **28**: 1451-1456 [PMID: 15920067 DOI: 10.2337/diacare.28.6.1451]

12 **Hayner NS**, Kjelsberg MO, Epstein FH, Francis T. Carbohydrate tolerance and diabetes in a total community, tecumseh, michigan. 1. effects of age, sex, and test conditions on one-hour glucose tolerance in adults. *Diabetes* 1965; **14**: 413-423 [PMID: 14318589 DOI: 10.2337/diab.14.7.413]

13 **de Nobel E**, van't Laar A. The size of the loading dose as an important determinant of the results of the oral glucose tolerance test: a study in subjects with slightly impaired glucose tolerance. *Diabetes* 1978; **27**: 42-48 [PMID: 620880 DOI: 10.2337/diab.27.1.42]

14 **Sisk CW**, Burnham CE, Stewart J, McDonald GW. Comparison of the 50 and 100 gram oral glucose tolerance test. *Diabetes* 1970; **19**: 852-862 [PMID: 5480738 DOI: 10.2337/diab.19.11.852]

15 WHO Expert Committee on Diabetes Mellitus: second report. *World Health Organ Tech Rep Ser* 1980; **646**: 1-80 [PMID: 6771926]

16 Diabetes mellitus. Report of a WHO Study Group. *World Health Organ Tech Rep Ser* 1985; **727**: 1-113 [PMID: 3934850]

17 Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1997; **20**: 1183-1197 [PMID: 9203460 DOI: 10.2337/diacare.20.7.1183]

18 **Harris MI**, Hadden WC, Knowler WC, Bennett PH. International criteria for the diagnosis of diabetes and impaired glucose tolerance. *Diabetes Care* 1985; **8**: 562-567 [PMID: 4075941 DOI: 10.2337/diacare.8.6.562]

19 **Modan M**, Halkin H, Karasik A, Lusky A. Effectiveness of glycosylated hemoglobin, fasting plasma glucose, and a single post load plasma glucose level in population screening for glucose intolerance. *Am J Epidemiol* 1984; **119**: 431-444 [PMID: 6702817]

20 **Modan M**, Harris MI. Fasting plasma glucose in screening for NIDDM in the U.S. and Israel. *Diabetes Care* 1994; **17**: 436-439 [PMID: 7741837 DOI: 10.2337/diacare.17.5.436]

21 **Finch CF**, Zimmet PZ, Alberti KG. Determining diabetes prevalence: a rational basis for the use of fasting plasma glucose concentrations? *Diabet Med* 1990; **7**: 603-610 [PMID: 2146068 DOI: 10.1111/j.1464-5491.1990.tb01457.x]

22 **Haffner SM**, Rosenthal M, Hazuda HP, Stern MP, Franco LJ. Evaluation of three potential screening tests for diabetes mellitus in a biethnic population. *Diabetes Care* 1984; **7**: 347-353 [PMID: 6468231 DOI: 10.2337/diacare.7.4.347]

23 **Blunt BA**, Barrett-Connor E, Wingard DL. Evaluation of fasting plasma glucose as screening test for NIDDM in older adults. Rancho Bernardo Study. *Diabetes Care* 1991; **14**: 989-993 [PMID: 1797513 DOI: 10.2337/diacare.14.11.989]

24 **Taylor R**, Zimmet P. Limitation of fasting plasma glucose for the diagnosis of diabetes mellitus. *Diabetes Care* 1981; **4**: 556-558 [PMID: 7347665 DOI: 10.2337/diacare.4.5.556]

25 **Hanson RL**, Nelson RG, McCance DR, Beart JA, Charles MA, Pettitt DJ, Knowler WC. Comparison of screening tests for non-insulin-dependent diabetes mellitus. *Arch Intern Med* 1993; **153**: 2133-2140 [PMID: 8379805 DOI: 10.1001/archinte.1993.00410180083010]

26 **McCance DR**, Hanson RL, Charles MA, Jacobsson LT, Pettitt DJ, Bennett PH, Knowler WC. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. *BMJ* 1994; **308**: 1323-1328 [PMID: 8019217 DOI: 10.1136/bmj.308.6940.1323]

27 **Genuth S**, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P. Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care* 2003; **26**: 3160-3167 [PMID: 14578255 DOI: 10.2337/diacare.26.11.3160]

28 **Shaw JE**, Zimmet PZ, Hodge AM, de Courten M, Dowse GK, Chitson P, Tuomilehto J, Alberti KG. Impaired fasting glucose: how low should it go? *Diabetes Care* 2000; **23**: 34-39 [PMID: 10857965 DOI: 10.2337/diacare.23.1.34]

29 **Forouhi NG**, Balkau B, Borch-Johnsen K, Dekker J, Glumer C, Qiao Q, Spijkerman A, Stolk R, Tabac A, Wareham NJ. The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group. *Diabetologia* 2006; **49**: 822-827 [PMID: 16525842 DOI: 10.1007/s00125-006-0189-4]

30 **Gillett MJ**. International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes: Diabetes Care 2009; 32(7): 1327-1334. *Clin Biochem Rev* 2009; **30**: 197-200 [PMID: 20011212]

31 **Gambino R**. Glucose: a simple molecule that is not simple to quantify. *Clin Chem* 2007; **53**: 2040-2041 [PMID: 18267929 DOI: 10.1373/clinchem.2007.094466]

32 **Petersen PH**, Jørgensen LG, Brandslund I, De Fine Olivarius N, Stahl M. Consequences of bias and imprecision in measurements of glucose and hba1c for the diagnosis and prognosis of diabetes mellitus. *Scand J Clin Lab Invest Suppl* 2005; **240**: 51-60 [PMID: 16112960 DOI: 10.1080/00365510500236135]

33 **Selvin E**, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes. *Arch Intern Med* 2007; **167**: 1545-1551 [PMID: 17646610 DOI: 10.1001/archinte.167.14.1545]

34 **Lorenzo C**, Haffner SM. Performance characteristics of the new definition of diabetes: the insulin resistance atherosclerosis study. *Diabetes Care* 2010; **33**: 335-337 [PMID: 19880585 DOI: 10.2337/dc09-1357]

35 **Kramer CK**, Araneta MR, Barrett-Connor E. A1C and diabetes diagnosis: The Rancho Bernardo Study. *Diabetes Care* 2010; **33**: 101-103 [PMID: 19837792 DOI: 10.2337/dc09-1366]

36 **Olson DE**, Rhee MK, Herrick K, Ziemer DC, Twombly JG, Phillips LS. Screening for diabetes and pre-diabetes with proposed A1C-based diagnostic criteria. *Diabetes Care* 2010; **33**: 2184-2189 [PMID: 20639452 DOI: 10.2337/dc10-0433]

37 **Nakagami T**, Tajima N, Oizumi T, Karasawa S, Wada K, Kameda W, Susa S, Kato T, Daimon M. Hemoglobin A1c in predicting progression to diabetes. *Diabetes Res Clin Pract* 2010; **87**: 126-131 [PMID: 19945760 DOI: 10.1016/j.diabres.2009.11.001]

38 **Bae JC**, Rhee EJ, Lee WY, Park SE, Park CY, Oh KW, Park SW, Kim SW. Optimal range of HbA1c for the prediction of future diabetes: a 4-year longitudinal study. *Diabetes Res Clin Pract* 2011; **93**: 255-259 [PMID: 21676480 DOI: 10.1016/j.diabres.2011.05.028]

39 **Dankner R**, Bergman M, Danoff A, Qureshi S, Whitford I, Kaviani N, Dynkevich Y, Roth J. The metabolic deterioration that antedates diabetes: personal trajectories of HbA(1c) and fasting glucose as early indicators and possible triggers for intervention. *Diabetes Metab Res Rev* 2013; **29**: 1-7 [PMID: 23175191 DOI: 10.1002/dmrr.2373]

40 **Mostafa SA**, Khunti K, Srinivasan BT, Webb D, Gray LJ, Davies MJ. The potential impact and optimal cut-points of using glycated haemoglobin, HbA1c, to detect people with impaired glucose regulation in a UK multi-ethnic cohort. *Diabetes Res Clin Pract* 2010; **90**: 100-108 [PMID: 20633944 DOI: 10.1016/j.diabres.2010.06.008]

41 **Tsugawa Y**, Mukamal KJ, Davis RB, Taylor WC, Wee CC. Should the hemoglobin A1c diagnostic cutoff differ between blacks and whites? A cross-sectional study. *Ann Intern Med* 2012; **157**: 153-159 [PMID: 22868832 DOI: 10.7326/0003-4819-157-3-201208070-00004]

42 **Colagiuri S**, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. *Diabetes Care* 2011; **34**: 145-150 [PMID: 20978099 DOI: 10.2337/dc10-1206]

43 **Tapp RJ**, Zimmet PZ, Harper CA, de Courten MP, McCarty DJ, Balkau B, Taylor HR, Welborn TA, Shaw JE. Diagnostic thresholds for diabetes: the association of retinopathy and albuminuria with glycaemia. *Diabetes Res Clin Pract* 2006; **73**: 315-321 [PMID: 16644057 DOI: 10.1016/j.diabres.2006.02.008]

44 **Sabanayagam C**, Liew G, Tai ES, Shankar A, Lim SC, Subramaniam T, Wong TY. Relationship between glycated haemoglobin and microvascular complications: is there a natural cut-off point for the diagnosis of diabetes? *Diabetologia* 2009; **52**: 1279-1289 [PMID: 19387611 DOI: 10.1007/s00125-009-1360-5]

45 **Xin Z**, Yuan MX, Li HX, Hua L, Feng JP, Shi J, Zhu XR, Cao X, Yang JK. Evaluation for fasting and 2-hour glucose and HbA1c for diagnosing diabetes based on prevalence of retinopathy in a Chinese population. *PLoS One* 2012; **7**: e40610 [PMID: 22808204 DOI: 10.1371/journal.pone.0040610]

46 **Cho NH**, Kim TH, Woo SJ, Park KH, Lim S, Cho YM, Park KS, Jang HC, Choi SH. Optimal HbA1c cutoff for detecting diabetic retinopathy. *Acta Diabetol* 2013; **50**: 837-842 [PMID: 23354926 DOI: 10.1007/s00592-013-0452-3]

47 **Selvin E**, Ning Y, Steffes MW, Bash LD, Klein R, Wong TY, Astor BC, Sharrett AR, Brancati FL, Coresh J. Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. *Diabetes* 2011; **60**: 298-305 [PMID: 20978092 DOI: 10.2337/db10-1198]

48 **Tsugawa Y**, Takahashi O, Meigs JB, Davis RB, Imamura F, Fukui T, Taylor WC, Wee CC. New diabetes diagnostic threshold of hemoglobin A(1c) and the 3-year incidence of retinopathy. *Diabetes* 2012; **61**: 3280-3284 [PMID: 22891221 DOI: 10.2337/db12-0103]

49 **van Leiden HA**, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD, Polak BC. Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study. *Arch Ophthalmol* 2003; **121**: 245-251 [PMID: 12583792]

50 **Bower JK**, Brancati FL, Selvin E. No ethnic differences in the association of glycated hemoglobin with retinopathy: the national health and nutrition examination survey 2005-2008. *Diabetes Care* 2013; **36**: 569-573 [PMID: 23069841 DOI: 10.2337/dc12-0404]

51 **Zhang Y**, Hu G, Yuan Z, Chen L. Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis. *PLoS One* 2012; **7**: e42551 [PMID: 22912709 DOI: 10.1371/journal.pone.0042551]

52 **Selvin E**, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. *Ann Intern Med* 2004; **141**: 421-431 [PMID: 15381515 DOI: 10.7326/0003-4819-141-6-200409210-00007]

53 **Diabetes Prevention Program Research Group**. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. *Diabet Med* 2007; **24**: 137-144 [PMID: 17257275 DOI: 10.1111/j.1464-5491.2007.02043.x]

54 **Yu T**, Mitchell P, Berry G, Li W, Wang JJ. Retinopathy in older persons without diabetes and its relationship to hypertension. *Arch Ophthalmol* 1998; **116**: 83-89 [PMID: 9445212]

55 **Dunstan DW**, Zimmet PZ, Welborn TA, Cameron AJ, Shaw J, de Courten M, Jolley D, McCarty DJ. The Australian Diabetes, Obesity and Lifestyle Study (AusDiab)--methods and response rates. *Diabetes Res Clin Pract* 2002; **57**: 119-129 [PMID: 12062857 DOI: 10.1016/S0168-8227(02)00025-6]

56 **Wong TY**, Barr EL, Tapp RJ, Harper CA, Taylor HR, Zimmet PZ, Shaw JE. Retinopathy in persons with impaired glucose metabolism: the Australian Diabetes Obesity and Lifestyle (AusDiab) study. *Am J Ophthalmol* 2005; **140**: 1157-1159 [PMID: 16376677 DOI: 10.1016/j.ajo.2005.07.030]

57 **Tapp RJ**, Shaw JE, Harper CA, de Courten MP, Balkau B, McCarty DJ, Taylor HR, Welborn TA, Zimmet PZ. The prevalence of and factors associated with diabetic retinopathy in the Australian population. *Diabetes Care* 2003; **26**: 1731-1737 [PMID: 12766102 DOI: 10.2337/diacare.26.6.1731]

58 **Lamparter J**, Raum P, Pfeiffer N, Peto T, Höhn R, Elflein H, Wild P, Schulz A, Schneider A, Mirshahi A. Prevalence and associations of diabetic retinopathy in a large cohort of prediabetic subjects: the Gutenberg Health Study. *J Diabetes Complications* 2014; **28**: 482-487 [PMID: 24630763 DOI: 10.1016/j.jdiacomp.2014.02.008]

59 **Cugati S**, Cikamatana L, Wang JJ, Kifley A, Liew G, Mitchell P. Five-year incidence and progression of vascular retinopathy in persons without diabetes: the Blue Mountains Eye Study. *Eye* (Lond) 2006; **20**: 1239-1245 [PMID: 16167076 DOI: 10.1038/sj.eye.6702085]

60 **Wong TY**, Klein R, Amirul Islam FM, Cotch MF, Couper DJ, Klein BE, Hubbard LD, Sharrett AR. Three-year incidence and cumulative prevalence of retinopathy: the atherosclerosis risk in communities study. *Am J Ophthalmol* 2007; **143**: 970-976 [PMID: 17399675 DOI: 10.1016/j.ajo.2007.02.020]

61 **Klein R**, Klein BE, Moss SE, Wang Q. Hypertension and retinopathy, arteriolar narrowing, and arteriovenous nicking in a population. *Arch Ophthalmol* 1994; **112**: 92-98 [PMID: 8285901]

62 **Cugati S**, Mitchell P, Wang JJ. Do retinopathy signs in non-diabetic individuals predict the subsequent risk of diabetes? *Br J Ophthalmol* 2006; **90**: 928-929 [PMID: 16782966 DOI: 10.1136/bjo.2006.095943]

63 **Klein R**, Klein BE, Moss SE, Wong TY. The relationship of retinopathy in persons without diabetes to the 15-year incidence of diabetes and hypertension: Beaver Dam Eye Study. *Trans Am Ophthalmol Soc* 2006; **104**: 98-107 [PMID: 17471330]

64 **Plantinga LC**, Crews DC, Coresh J, Miller ER, Saran R, Yee J, Hedgeman E, Pavkov M, Eberhardt MS, Williams DE, Powe NR. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. *Clin J Am Soc Nephrol* 2010; **5**: 673-682 [PMID: 20338960 DOI: 10.2215/CJN.07891109]

65 **Melsom T**, Mathisen UD, Ingebretsen OC, Jenssen TG, Njølstad I, Solbu MD, Toft I, Eriksen BO. Impaired fasting glucose is associated with renal hyperfiltration in the general population. *Diabetes Care* 2011; **34**: 1546-1551 [PMID: 21593291 DOI: 10.2337/dc11-0235]

66 **Hu W**, Hao H, Yu W, Wu X, Zhou H. Association of elevated glycosylated hemoglobin A1c with hyperfiltration in a middle-aged and elderly Chinese population with prediabetes or newly diagnosed diabetes: a cross-sectional study. *BMC Endocr Disord* 2015; **15**: 47 [PMID: 26363801 DOI: 10.1186/s12902-015-0043-0]

67 **Greene SA**, Dalton RN, Turner C, Haycock GB, Chantler C. Hyperglycemia with and without glycosuria: effect on inulin and para-amino hippurate clearance. *Kidney Int* 1987; **32**: 896-899 [PMID: 3430968 DOI: 10.1038/ki.1987.292]

68 **Metcalf PA**, Baker JR, Scragg RK, Dryson E, Scott AJ, Wild CJ. Microalbuminuria in a middle-aged workforce. Effect of hyperglycemia and ethnicity. *Diabetes Care* 1993; **16**: 1485-1493 [PMID: 8299438 DOI: 10.2337/diacare.16.11.1485]

69 **Kim CH**, Kim KJ, Kim BY, Jung CH, Mok JO, Kang SK, Kim HK. Prediabetes is not independently associated with microalbuminuria in Korean general population: the Korea National Health and Nutrition Examination Survey 2011-2012 (KNHANES V-2,3). *Diabetes Res Clin Pract* 2014; **106**: e18-e21 [PMID: 25271114 DOI: 10.1016/j.diabres.2014.09.004]

70 **Kannan MA**, Sarva S, Kandadai RM, Paturi VR, Jabeen SA, Borgohain R. Prevalence of neuropathy in patients with impaired glucose tolerance using various electrophysiological tests. *Neurol India* 2014; **62**: 656-661 [PMID: 25591680 DOI: 10.4103/0028-3886.149393]

71 **Sun CK**. Cardio-ankle vascular index (CAVI) as an indicator of arterial stiffness. *Integr Blood Press Control* 2013; **6**: 27-38 [PMID: 23667317 DOI: 10.2147/IBPC.S34423]

72 **Namekata T**, Shirai K, Tanabe N, Miyanishi K, Nakata M, Suzuki K, Arai C, Ishizuka N. Estimating the extent of subclinical arteriosclerosis of persons with prediabetes and diabetes mellitus among Japanese urban workers and their families: a cross-sectional study. *BMC Cardiovasc Disord* 2016; **16**: 52 [PMID: 26911293 DOI: 10.1186/s12872-016-0230-6]

73 **Bild DE**, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR, Kronmal R, Liu K, Nelson JC, O'Leary D, Saad MF, Shea S, Szklo M, Tracy RP. Multi-Ethnic Study of Atherosclerosis: objectives and design. *Am J Epidemiol* 2002; **156**: 871-881 [PMID: 12397006 DOI: 10.1093/aje/kwf113]

74 **Stacey RB**, Leaverton PE, Schocken DD, Peregoy JA, Bertoni AG. Prediabetes and the association with unrecognized myocardial infarction in the multi-ethnic study of atherosclerosis. *Am Heart J* 2015; **170**: 923-928 [PMID: 26542500 DOI: 10.1016/j.ahj.2015.08.003]

75 **Barr EL**, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, Cameron AJ, Dwyer T, Taylor HR, Tonkin AM, Wong TY, McNeil J, Shaw JE. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). *Circulation* 2007; **116**: 151-157 [PMID: 17576864 DOI: 10.1161/CIRCULATIONAHA.106.685628]

76 **Xu T**, Liu W, Cai X, Ding J, Tang H, Huang Y, Hu Y. Risk of Coronary Heart Disease in Different Criterion of Impaired Fasting Glucose: A Meta-Analysis. *Medicine (Baltimore)* 2015; **94**: e1740 [PMID: 26448033 DOI: 10.1097/MD.0000000000001740]

77 **Lee M**, Saver JL, Hong KS, Song S, Chang KH, Ovbiagele B. Effect of pre-diabetes on future risk of stroke: meta-analysis. *BMJ* 2012; **344**: e3564 [PMID: 22677795]

**P-Reviewer:** Cui WP, Ferroni P, Hegardt FG, Markopoulos AK, Mauricio D, Nishio K, Salceda R **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Table 1 Evolution of diagnostic criteria of diabetes mellitus**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **WHO 1965** | **WHO 1980** | **WHO 1985** | **ADA1997**  **WHO 1999** | **ADA 2003** | **IEC 2009**  **ADA 2010**  **WHO 2011** |
| **IFG** | Not defined | Not defined | Not defined | Fasting  ≥ 6.11 to < 7 mmol/L and Post glucose (if measured) < 11.1 mmol/L | Fasting  **≥** 5.5 to < 7 mmol/L and Post glucose (if measured)  < 11.1 mmol/L | Fasting  **≥** 5.5 to < 7 mmol/L and Post glucose (if measured)  < 11.1 mmol/L or  HbA1C (5.7%-6.4%) |
| **IGT** | Post glucose  6.11-7.1 mmol/L | Fasting  < 8 mmol/L  and/or post glucose  ≥ 8 to < 11.1 mmol/L | Fasting  < 7.8 mmol/L  and/or Post glucose  ≥ 7.8 to < 11.1 mol/L | Fasting (if measured)  < 7 mmol/L  and post glucose  ≥ 7.8 to 11.1 mmol/L | Fasting  Not required  Post glucose  7.8 to 11.1 mmol/L | Fasting  Not required  Post glucose  7.8 to 11.1 mmol/L or HbA1C (5.7%-6.4%) |
| **DM** | Post glucose  > 7.22 mmol/L | Fasting  ≥ 8 mmol/L  and/or  post glucose  ≥ 11.1 mmol/**L** | Fasting  ≥ 7.8 mmol/L  and/or  post glucose  ≥ 11.1 mmol/L | Fasting  ≥ 7.8 mmol/L  and/or  post glucose  ≥ 11.1 mmol/L | Fasting  **≥** 7 mmol/L  and/or  post glucose  ≥ 11.1 mmol/L | Fasting  ≥ 7 mmol/L  or  Post glucose  ≥ 11.1 mmol/L and/or HbA1C  ≥ 6.5% |

IFG: Impaired fasting glucose; IGT: Impaired glucose tolerance; DM: Diabetes mellitus; IEC: International Expert Committee; ADA: American Diabetes Association; WHO: World Health Organization.

**Table 2 Longitudinal studies assessing the glycated hemoglobin thresholds for retinopathy**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Study population**  **characteristics** | **Assessment of retinopathy** | **Method of determining cutoff** | **Cut off** |
| Tsugawa *et al*[48] | 3 yr  follow-up; Number = 19987  Japanese subjects;  age ≥ 21 yr;  diabetes not excluded | Nonmydriatic 45° retinal  photograph | Test for nonlinearity inmultivariate logistic regression models with restricted cubicspline  Multivariate logistic regressionwith categories of HbA1c as independent variable | Possible threshold at HbA1c levels between 6.0 and 7.0  6.5%-6.9% |
| van Leiden *et al*[49]  Hoorn study | 7.9-11.0 yr follow-up; Number = 233;  age 50-74 yr; analyses  in total study group and in  subjects without diabetes | Ophthalmoscopy and fundus photography | Logistic model with categoriesof HbA1c (adjusted for age, sex, hypertension, glucose metabolismcategory) | No threshold found |